MedAdvisor Limited (AU:AHE)
ASX:AHE
Want to see AU:AHE full AI Analyst Report?
Top Page
MedAdvisor Limited
(Sydney:AHE)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.02
Action:Reiterated
Date:05/15/26
The score is primarily constrained by weak financial performance, including sharp revenue contraction, deeply negative margins, and negative equity that elevates solvency risk. Technicals are also weak (below the 200DMA with negative MACD), though the oversold RSI slightly offsets the downside risk. Valuation provides limited support due to the negative P/E and lack of dividend data.
Positive Factors
Platform business & network
MedAdvisor operates a pharmacy-focused software platform plus a consumer medication app, creating two-sided network effects between pharmacies and patients. This supports recurring engagement, sticky workflows and cross-sell opportunities, providing a durable competitive advantage in medication management.
Negative Factors
Steep revenue decline
A ~39% revenue contraction materially erodes scale economics and weakens the platform's ability to invest in product, sales and partner relationships. Sustained top-line decline undermines long-term competitiveness and makes returning to profitable scale more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform business & network
MedAdvisor operates a pharmacy-focused software platform plus a consumer medication app, creating two-sided network effects between pharmacies and patients. This supports recurring engagement, sticky workflows and cross-sell opportunities, providing a durable competitive advantage in medication management.
Read all positive factors
MedAdvisor Limited (AHE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$12.75M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue Growth-71.80%
EPS Growth-1044.71%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.07
Shares Outstanding637,676,800
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$110.67M
MedAdvisor Limited Business Overview & Revenue Model
Company Description
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-drive...
How the Company Makes Money
null...
MedAdvisor Limited Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
35
Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 62.99M | 122.11M | 97.96M | 67.75M | 38.77M |
| Gross Profit | -135.06K | 74.25M | 59.41M | 34.99M | 21.31M |
| EBITDA | -57.25M | 7.05M | -3.03M | -11.29M | -13.59M |
| Net Income | -60.21M | 792.13K | -11.31M | -17.35M | -13.95M |
Balance Sheet | |||||
| Total Assets | 39.84M | 98.78M | 95.91M | 78.57M | 81.04M |
| Cash, Cash Equivalents and Short-Term Investments | 10.30M | 15.58M | 14.20M | 7.58M | 7.15M |
| Total Debt | 17.40M | 12.61M | 13.09M | 13.41M | 9.16M |
| Total Liabilities | 38.79M | 47.20M | 47.45M | 51.40M | 32.07M |
| Stockholders Equity | 1.05M | 51.58M | 48.46M | 34.55M | 48.45M |
Cash Flow | |||||
| Free Cash Flow | -14.37M | 5.12M | -1.63M | -548.13K | -12.94M |
| Operating Cash Flow | -14.37M | 5.19M | -1.45M | -236.32K | -12.54M |
| Investing Cash Flow | -2.18M | -2.80M | -3.23M | -290.79K | -43.36M |
| Financing Cash Flow | 11.34M | -831.97K | 12.42M | 1.86M | 50.72M |
MedAdvisor Limited Technical Analysis
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHE, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for AU:AHE.
MedAdvisor Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
MedAdvisor Limited Corporate Events
Adheris Health Director Increases Equity Stake with On‑Market Share Purchases
May 12, 2026
Adheris Health director John Ciccio has increased his direct holding in the company by acquiring 323,541 fully paid ordinary shares through on‑market trades conducted between 5 and 11 May 2026. The purchases were made at prices of $0.02 and ...
MedAdvisor’s Adheris Health Deepens Pharmacy-Led Patient Engagement Focus
Apr 28, 2026
MedAdvisor’s Adheris Health unit is reinforcing its role as a leader in pharmacy-led patient engagement, working with global pharma and major U.S. pharmacy chains to deliver personalised medication support. The business serves a broad nation...
Adheris Health Revenue Falls but Cost Cuts and Platform Upgrades Aim at Q4 Cash Break-Even
Apr 27, 2026
Adheris Health reported Q3 FY26 operating revenue of $5.4 million, down 23.9% year on year, with gross profit falling to $2.1 million and gross margin slipping to 39.7% amid weaker customer renewals, smaller deal sizes and pharma budget pressures....
Adheris Health Tightens Governance With Updated Securities Trading Policy
Apr 22, 2026
Adheris Health has updated its Securities Trading Policy in line with ASX requirements, releasing a revised framework that governs how its officers and employees can trade in the company’s securities. The board has resolved to replace the pr...
Adheris Health Grants 60 Million Long-Dated Employee Options
Apr 9, 2026
Adheris Health Limited has notified the market of the issue of 60 million unquoted options under an employee incentive scheme. The options, which are not intended to be quoted on the ASX, carry an exercise price of $0.03 and expire on 30 June 2035...
Adheris Health Options Lapse After Vesting Conditions Not Met
Apr 9, 2026
Adheris Health Limited has notified the market that 8,889 AHEAT options, which were due to expire in March 2031, have lapsed because their specified conditions were not, or could no longer be, satisfied. The cessation of these conditional rights m...
Adheris Health Grants CEO 30 Million Long-Term Incentive Options
Apr 9, 2026
Adheris Health Limited has disclosed a change in director’s interests, confirming that Managing Director and CEO John Ciccio has been granted 30 million unlisted options under the company’s 2026 long-term incentive plan. The options, e...
Adheris Health Shareholders Back Incentive Plan Changes at Extraordinary Meeting
Mar 12, 2026
Adheris Health Limited has reported that all resolutions put to shareholders at its Extraordinary General Meeting on 12 March 2026 were passed by the required majority via poll. Investors approved amendments to the company’s Long Term Incent...
Adheris Health Director Increases Shareholding via On-Market Trades
Mar 11, 2026
Adheris Health Limited has disclosed a change in director Lucas Merrow’s holdings, with the executive increasing his direct interest in the company through on-market share purchases. Between 4 and 9 March 2026, Merrow acquired 695,000 fully ...
Adheris Health director lifts stake with on-market share purchase
Mar 9, 2026
MedAdvisor subsidiary Adheris Health has disclosed a substantial on-market share purchase by director Lucas Merrow, signalling increased insider confidence in the company. Merrow acquired 890,000 fully paid ordinary shares on 3 March 2026 at an av...
Adheris Health Director Catherine Hill Increases Shareholding via On-Market Purchase
Mar 8, 2026
Adheris Health Limited has disclosed a change in the interests of director Catherine (Kate) Jane Hill following on-market share purchases. Hill acquired 1,500,000 fully paid ordinary shares on 2 March 2026 at an average price of $0.020 per share, ...
Adheris Health Updates Virtual Access Details for March EGM
Mar 2, 2026
Adheris Health Limited has updated the virtual access details for its extraordinary general meeting scheduled for 12 March 2026, introducing a new Zoom link designed to offer improved functionality for shareholders. The company stated that the cha...
Adheris Health clarifies 1H FY26 profit boosted by ANZ business sale
Feb 27, 2026
Adheris Health has clarified its previously released first-half FY26 results to explicitly state that reported EBITDA of $10.7 million and NPAT of $7.3 million were boosted by a $17.5 million profit on the sale of its ANZ business. The correction ...
Adheris Health Slashes Costs and Resets Strategy as Revenue Halves in 1H FY26
Feb 27, 2026
Adheris Health reported a sharp contraction in 1H FY26 revenue to A$23.3 million, down 49%, and a 58.5% fall in gross profit amid lower U.S. vaccination volumes and smaller pharma deal sizes, which also compressed gross margins. Despite weaker top...
Adheris Health posts profit surge and balance-sheet turnaround despite revenue slump
Feb 27, 2026
Adheris Health Limited reported a sharp turnaround in profitability for the half-year to 31 December 2025, with profit after tax attributable to owners rising 423.9% to $7.35 million, despite revenue from continuing operations falling 49% to $23.3...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.